Belépés

NCT07528391Toborzás még nem indult

Comorbidity-Oriented Primary Care and Integrated Management for Hypertension and Diabetes Mellitus

Comorbidity-Oriented Primary Care and Integrated Management for Hypertension and Diabetes Mellitus: A Cluster Randomised Controlled Trial in Rural China

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. ápr. 14.

Rövid összefoglaló (regiszter, angolul)

The COMPACT-HTDM study is a parallel, two-arm cluster randomized controlled trial designed to evaluate a comorbidity-oriented integrated primary care management model for elderly patients with coexisting hypertension and type 2 diabetes mellitus in community health centers and township health centers. The trial aims to determine whether an integrated comorbidity management package can improve metabolic control and cardiovascular risk management compared with usual disease-specific care in routine primary care settings. Clusters are primary care facilities randomized 1:1 to intervention or control by an independent statistician using a computer-generated random sequence. Patients aged 60-74 years with diagnosed hypertension and type 2 diabetes for at least six months and recent use of chronic disease management services at the study site will be recruited through chronic disease registries. The intervention includes comorbidity-focused medication optimization and safety management, integrated lifestyle management, self-management and community support, training for primary care staff, standardized toolkits and workflow embedding, an integrated comorbidity management platform, and feedback/incentive mechanisms. The control group will continue current standard primary care management for hypertension and diabetes under existing national guidelines. Participants will be followed for six months, with possible extension to 12 months for longer-term outcomes. The primary outcome is the proportion of participants achieving both blood pressure and glycemic control targets, defined as SBP/DBP \<130/80 mmHg and HbA1c \<7.0%. Secondary outcomes include BMI, blood lipids, medication adherence, lifestyle behaviors, follow-up completion, referral rate, and safety events such as hypoglycemia and hypotension; implementation outcomes include acceptability, fidelity, and feasibility.

Állapot (regiszter)
Toborzás még nem indult
Vizsgálattípus
Beavatkozással járó
Résztvevők száma
960 (tervezett)
Első benyújtás
2026. ápr. 1.
Kezdés
2026. máj. 1.
Elsődleges befejezés
2027. ápr. 30.
Fő szponzor
Nanchang University
NCT-szám
NCT07528391

Mit vállalsz

  • Vizsgálat típusa: Beavatkozással járó
  • Tervezett résztvevők: 960
  • 2026. máj. 1. és az elsődleges befejezés (2027. ápr. 30.) között
  • Nincs megadott helyszín, ország nélkül
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Más betegség

  • Facilities currently participating in other intervention studies or pilot programs targeting hypertension and/or diabetes management that may interfere with the study intervention.
  • Severe cognitive impairment or psychiatric illness affecting participation or follow-up.

Egyéb

  • Cluster Level (Primary Care Facilities):
  • Facilities with major organizational instability (e.g., restructuring, closure, or significant staff turnover) that would affect implementation or follow-up.
    • Individual Level:
  • Anticipated inability to complete 6-month follow-up.

Kiket keres a vizsgálat

  • Cluster level (primary care facilities):
  • Township health centers or community health service centers that provide routine primary care management services for both hypertension and diabetes.
  • Agree to participate in cluster randomization and study procedures.
  • Have basic capacity for chronic disease follow-up and data recording.
    • Individual participant level (patients):
  • Aged 60 to 74 years.
  • Diagnosed with hypertension and type 2 diabetes mellitus for at least 6 months.
  • Received at least one chronic disease management service at the participating study site within the past 6 months.
  • Able to provide written informed consent.

Életkor a regiszterben: 60 év – 74 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.